Home Investors Stock & Rating Information Shareholder Return Shareholder Return Important Notice This website contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, or in different dosages. Nothing contained herein should be considered a solicitation, promotion or advertisement for any drug including the ones under development on this web site. Any information on the products contained herein is not intended to provide medical advice nor should be used as a substitute for the advice provided by your physician or other healthcare provider. I Agree Basic Policy on Shareholder Return: The Company works aggressively towards increasing enterprise value on a continual basis and, as a consequence, improves its return to shareholders. While putting priority on business investment to assure future growth, the Company strives to increase dividend payments stably and continuously based on its medium- to long-term profit growth on a consolidated basis. Further, the Company flexibly acquires its own shares whenever necessary to increase capital efficiency and shareholder return. Dividend Record Date for Dividend: Year-end dividend - March 31 Interim dividend - September 30 Announcement of the 17th Interim Dividend The company would like to inform you that the following resolutions have been made at the Board of Directors meeting held on October 29, 2021 regarding the payment of interim dividends for the 17th term (April 1, 2021 to March 31, 2022). Interim dividend: 25 yen per share Effective date of interim dividend: Wednesday, December 1, 2021 (Payment start date) Historical Data of Dividend and DOE IFRS Dividend (Unit: Yen / share) DOE (%) Interim dividend Year-end dividend Annual dividend Annual DOE FY2021 25 25 (planned) 50 (planned) FY2020 21 21 42 5.8 FY2019 20 20 40 5.9 FY2018 19 19 38 5.8 FY2017 18 18 36 5.7 Notes: The Astellas Group has adopted the International Financial Reporting Standards ("IFRS"), effective from the fiscal year ended March 31, 2014. Notes: In accordance with the Company's Articles of Incorporation, if cash dividends are not claimed for three (3) full years from the day of commencement of payment, the Company shall be relieved of the obligation to make such payment. Share Buyback and Cancellation of Treasury Stock Share Buyback Acquisition period Shares acquired Total acquisition cost (thousand yen) PDF Nov. 1 2019 - Jan. 31 2020 27,036,100 49,999,815 (pdf 179KB) Feb. 1 - Mar. 20 2019 35,368,900 59,999,863 (pdf 167KB) Jun. 1 - Sep. 20 2018 55,475,800 99,999,960 (pdf 301KB) Feb. 1 - Mar. 23 2018 39,577,500 59,999,993 (pdf 167KB) Jul. 31 - Oct. 31 2017 49,298,000 69,999,960 (pdf 121KB) Feb. 1 - Mar. 22 2017 30,000,000 45,525,514 (pdf 189KB) Oct. 31 - Dec. 22 2016 30,000,000 45,895,995 (pdf 189KB) Read More Cancellation of Treasury Stock Date of cancellation Shares cancelled Shares cancelled as a percentage of all outstanding shares issued prior to the cancellation PDF Feb 14, 2020 27,036,100 1.45% (pdf 179KB) May 31, 2019 91,000,000 4.60% (pdf 279KB) May 31, 2018 89,000,000 4.30% (pdf 281KB) May 31, 2017 85,000,000 3.95% (pdf 263KB) June 20, 2016 68,000,000 3.06% (pdf 74KB) Read More INVESTORS Corporate Strategic Plan 2021 Financial Information Annual Report IR Library IR Calendar Stock & Rating Information Shareholders Meeting Shareholder Return Current Share Status Chart Issuer Rating Analyst Coverage Cautionary Statement Bottom footer menu SITE MAP PRIVACY POLICY ACCESSIBILITY TERMS OF USE CONTACT US DISASTER INFORMATION FOR EMPLOYEES © Astellas Pharma Inc.